You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations
SBC: PHOTOSONOX LLC Topic: NIBIBABSTRACT: Cutaneous vascular malformations (CVM), such as port wine stain (PWS) which occurs in 0.3–0.5% of newborns, are often a cause of great concern to patients for both medical and cosmetic reasons. Laser irradiation with flashlamp-pumped pulsed dye lasers, i.e. photothermolysis therapy (PTT), is currently the gold standard treatment for PWS. Most patients with PWS, however, fail to clear c ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of a topical fixed-dose combination drug for peripheral neuropathic pain.
SBC: WinSanTor, Inc. Topic: NINDSPROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia
SBC: BRIDGENE BIOSCIENCES INC Topic: 102PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Intrapartum Transabdominal Fetal Pulse Oximetry: Demonstration in Ewe Models
SBC: Storx Technologies, Inc. Topic: NICHDProject Summary Despite significant cost and clear evidence of health risks associated with Cesarean section surgeries, an unnecessarily large number of infants are delivered via Cesarean section (C- Section) surgeries. The high rate of C-section in the US, relative to globally accepted norms, and the associated additional cost and complications are in part, due to high false positive rate of intr ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic Opioids
SBC: SEACOAST SCIENCE, INC. Topic: NIDAAbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA
SBC: REJUVENATION TECHNOLOGIES INC Topic: 400Abstract Rejuvenation Technologies Inc. (RTI) aims to prevent liver fibrosis in alcoholic hepatitis (AH) by enhancing liver regenerative capacity. AH is an acute form of alcoholic liver disease with mortality of up to 50% within 1 month of presentation. Most AH patients exhibit advanced fibrosis/cirrhosis, which contributes to acute-on-chronic liver failure. RTI will ameliorate/prevent this fibros ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Efficacy of a novel small-molecule splicing modulator in chronic lymphocytic leukemia (CLL)
SBC: Wildflower Biopharma Inc Topic: 102Project Summary/Abstract Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in Western countries. Despite recent treatment advances, CLL remains incurable. In the era of emerging targeted therapies, disease progression and relapse increasingly are key challenges faced by CLL patients. Therefore, there is an ongoing need for the identification of targetable vulnerabilities in t ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy
SBC: ENDECTRA LLC Topic: 102PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Pharmacological chaperones for the treatment of Open-Angle Glaucoma
SBC: Viewpoint Therapeutics, Inc. Topic: NEIOpen-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Reversal of Tau Pathology with MSUT2 siRNA Conjugates
SBC: DTx Pharma, Inc. Topic: NIAProject Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health